PathoBlock was founded in 2022 in Berlin. Instead of developing yet another antibiotic,
to which resistance can be acquired, PathoBlock developed a novel treatment mechanism that
prevents bacterial infections early on. It thereby also prevents the development of resistance combined
with less side effects.
